RCKT
RocketANasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
Current thesis
KRESLADI approval removes a major regulatory overhang, adds a PRV monetization lever, and leaves upside tied to cardiac programs if Danon re-derisks and PKP2 continues to show biologic activity [#8-K-2026-03-27] [#10-K-2026-02-26].
Posture
Constructive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +11.0.
What can break
Danon RP-A501 remains the main downside source if the next three-patient review is mixed or reveals recurring safety/tolerability issues.
Momentum
76
Value
41
Sentiment
77
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $4.60 · Bull $7.50 · Bear $2.20
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-20
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $9.39
Why
Momentum76 · Δ7d +1.4
Value41 · Δ7d +0.0
Sentiment77 · Δ7d +11.0
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Sentiment · See AI snapshot
Momentum
76
26% active weight
Current posture
7d trendImproving
Δ7d
+1.4
Δ21d
+68.8
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.1
Sentiment
77
34% active weight
Current posture
7d trendImproving
Δ7d
+11.0
Δ21d
-9.6
Why this grade
Composite grade A. Momentum 75.6 / Value 41.1 / Sentiment 77.5
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$374.53M
Beta
0.48
Shares Out
109.19M
P/E (TTM) · Derived
-1.7
P/S (TTM)
-
P/FCF (TTM) · Derived
-2.13
Rev YoY
-
EPS YoY
-23.8%
Gross Margin
-
Op Margin
-
Net Debt
-$164.05M
Current Ratio
6.12
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology